

**MARYLAND PRESCRIPTION DRUG AFFORDABILITY STAKEHOLDER COUNCIL  
VIRTUAL MEETING  
Monday, June 24, 2024  
Minutes**

**Agenda Item 1**

**Call to Order:**

Co-Chair Lorriane Diana called the meeting to order at 2:01 PM.

**(Roll Call) Stakeholder Council Members Present:**

Angela Bryant, Steven Chen, Allison Ciborowski, Lorraine Diana, CRNP, John Elliot, Sherita Hill Golden MD, MHS., Jim Gutman, Deron Johnson, Barry Lipsy, Eric Morse, Marc Nicole, Hayley Park, Pharm.D., Mandi Poplawski, Pharm. D., Sean Tunis, MD, MSc.

**Agenda Item 2**

**April 29, 2024 Meeting Minutes**

Co-Chair Diana asked for a motion to approve the April 29, 2024 meeting minutes as submitted. Jim Gutman made the motion, which Sherita Golden seconded. The Stakeholder Council approved the minutes 11-2, one member abstaining.

**Action: Minutes APPROVED**

**Agenda Item 3**

**Opportunity for Public Comment**

No persons registered for an opportunity to provide oral public comment. No written comments were received.

**Agenda Item 4**

**Cost Review Process Update- Presentation and Discussion**

Executive Director Andrew York provided an overview of the Cost Review Study timeline including the Board's selection of six drugs for the cost review study..

- Dr. York provided information concerning Dupixent, Farxiga, Jardiance, Ozempic, Trulicity, and Skyrizi, as well as responded to questions by clarifying the identification of NDC and therapeutic alternatives.
- Comments concerning the drugs selected for study are due by the close of business on Monday, July 22, 2024.
- Staff will release an FAQ on the cost review study process.
- Draft Request for Information (RFI) forms were sent for comment. Mr. York explained how entities are asked to submit an RFI. An entity has 30 days from the posting or

transmission of the RFI to submit the requested information. An entity may request one 30-day extension of time.

- Board staff requested feedback concerning the Stakeholder Council’s experience in discussing and providing input concerning the drugs referred by the Board.

#### **Agenda Item 5**

#### **Upper Payment Limit Action Plan Update**

Mr. York provided an update on the Upper Payment Limit Action Plan noting that the PDASC will have an opportunity to provide input on the draft Upper Payment Limit Action Plan.

#### **Agenda Item 6**

#### **Administrative Update**

- Ms. Shaklee advised that the Board adopted proposed amendments to COMAR 14.01.02, Prescription Drug Affordability Fund. Public comment on the proposed regulations are due by the close of business on Monday, July 1, 2024.
- Recordings of future in-person Board meetings are available on the Maryland General Assembly (“MGA”) YouTube page. Going forward, recordings of Stakeholder Council meetings will be published on the PDAB website.
- The July Board meeting will be held on July 22, 2024, in person at the Miller Senate Office Building in Annapolis, MD. The meeting will also be live streamed on the MGA YouTube channel.

#### **Agenda Item 7**

#### **Co-Chair’s Update**

The next PDASC meeting will be held on August 26th, 2024 at 2:00PM. The PDASC will continue to meet virtually through the end of 2024.

#### **Agenda Item 8**

#### **Adjournment**

Co-Chair Diana thanked everyone for attending the meeting and asked for a motion to adjourn the meeting. Sean Tunis made the motion which was seconded by Jim Gutman.

**Adjourned at 2:56 PM.**